HC Bioscience Showcases Oligonucleotide Therapeutics Advancements at the 6th CMC-China International Pharmaceutical Expo

Aug 16, 2024 11:11 CST Updated 11:11

Haichang Biotech

Innovative Formulation Developer

2024Year8Month15Day-16Day, the 6thCMC-ChinaChina Pharmaceutical Industry Expo Grandly Opens. This expo focuses on the latest advancements in the entire pharmaceutical industry chain, attracting tens of thousands of industry elites. Dr. Yongsheng Yang, Senior Vice President of Haichang Biotech and Dean of the Nucleic Acid Innovation Research Institute, along with Chief Medical Officer Dr. Yuxin Men, delivered in-depth presentations on nucleic acid drug research and development as well as clinical applications.

Dr. Yongsheng Yang: Development and Regulatory Challenges of Small Nucleic Acid Drugs

Dr. Yang Yongsheng introduced the core technology, technical difficulties, regulatory considerations, and development strategies of small nucleic acid drugs. He also presented Haichang Biotech's innovative practices in nucleic acid drug delivery systems, drug design, and production processes, as well as how the company overcomes common industry challenges to advance nucleic acid drugs from laboratory research to clinical applications. Dr. Yang’s presentation showcased Haichang Biotech's profound expertise in this field and provided valuable insights for technological innovation within the industry.

Dr. Men Yuxin: Key Considerations for CGT Product Clinical Trials

Dr. Men Yuxin Delivered an In-Depth Presentation on the Core Aspects of Clinical Trials Related to Cell and Gene Therapies, Sharing Her Valuable Insights on the Design, Execution, and Result Analysis of Nucleic Acid Drug Clinical Trials. She Emphasized That Clinical Trials Are a Critical Step in Verifying the Safety and Efficacy of Nucleic Acid Drugs and Highlighted the Importance of Maintaining Close Communication with Regulatory Authorities. Dr. Men Advocates for the Rational UseNMPA/FDARegulatory resources, scientifically planned trial protocols, with particular emphasis on safety evaluation and management. Haichang Biotech consistently ensures the high quality of drugs and patient safety through rigorous clinical research.

Haichang Biotech at the SixthCMC-ChinaChina Pharmaceutical Industry ExpoDebut,Showed inSmallProfessional expertise in the field of nucleic acid drugs, while bringing inspiration for the future development of the biopharmaceutical industry. During this grand event, Haichang Biotech exchanged views with industry peers on the cutting-edge trends in biopharmaceuticals, togetherAssistThe High-Quality Development of China's Biomedical Industry.

About Haichang Biotech

Haichang Biotech, located in the China Medical Valley in Hangzhou, is a national high-tech enterprise mainly engaged in the innovative development of biopharmaceutical technologies. The company has independent innovation capabilities and a global intellectual property layout. Haichang Biotech closely focuses on“Share, Progress, Truth-seeking, Pragmatism”The core values, focusing on the development and industrialization of drug delivery systems, with an emphasis on small nucleic acid drugs,mRNADevelopment of innovative nucleic acid drugs such as vaccines and complex injectables. Currently, Injectable Paclitaxel (Albumin-bound) has been approved for marketing in China and the EU, with registration applications ongoing in multiple countries along the Belt and Road; small nucleic acids1New Drug ClassHC0301ObtainedFDAAndNMPADual Approval, Currently Conducting Global MulticenterIIPhase Clinical Trial;mRNABooster Shot of COVID-19 Vaccine ObtainedFDAApproved for clinical trials, marking the first China-produced drug to receive U.S. clinical approval.mRNAVaccine Products. The product pipeline covers areas such as infectious disease prevention, tumor immunotherapy, anti-tumor, and pain relief.